子宫内膜癌手术治疗后围术期与生存期2型糖尿病诊断的患病率:筛查与干预的机会?
该回顾性单机构队列研究纳入2014至2020年接受手术治疗的519例子宫内膜癌患者,围术期2型糖尿病(T2DM)诊断率为7.1%,中位随访29个月期间另有18.3%的患者达到T2DM诊断标准,合计25.4%被诊断为T2DM,多数在生存期诊断。
要点
- 围术期T2DM患者BMI显著高于无T2DM者(p=0.006)。
- 围术期T2DM组术后任一并发症发生率更高(p=0.01),血管并发症差异显著(p=0.005)。
- 生存期T2DM诊断与BMI(p<0.001)、围术期血糖(p<0.001)和HgbA1c(p=0.002)相关。
核心结论
- 在该回顾性子宫内膜癌队列中,25.4%被诊断为T2DM,其中多数在生存期诊断。
- 子宫内膜癌的手术治疗及后续监测为诊断高危患者的T2DM提供了机会。
研究设计与样本
- 经IRB批准的回顾性单机构队列研究,纳入2014至2020年接受手术治疗的子宫内膜癌患者,共519例符合纳入标准。
- 围术期定义为手术前30天至手术后30天;T2DM诊断定义为HgbA1c≥6.5%或随机血糖≥200 mg/dL。
- 采用单因素分析检查围术期T2DM后遗症和未来T2DM的预测因素。
主要发现
- 519例患者中37例(7.1%)在围术期被诊断为T2DM。
- 围术期T2DM患者BMI显著高于无T2DM者(p=0.006),但年龄(p=0.20)、种族/民族(p>0.05)和ECOG评分(p=0.19)无显著差异。
- 围术期T2DM组术后任一并发症发生率更高(p=0.01);术中并发症除血管并发症(p=0.005)外无显著差异。
- 中位随访29个月(范围11.6-49.0个月),队列中另有18.3%(n=88)达到T2DM诊断标准。
- BMI(p<0.001)、围术期血糖(p<0.001)和HgbA1c(p=0.002)显示生存期T2DM诊断风险。
临床怎么用
- 原文结论指出子宫内膜癌的手术治疗及后续监测为诊断高危患者的T2DM提供了机会。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the prevalence of Type 2 diabetes mellitus (T2DM) diagnoses during the peri-operative and survivorship periods in patients following surgical management of endometrial cancer (EC). METHODS: An IRB-approved, retrospective single-institution cohort study was performed in patients who underwent surgical management of EC from 2014 to 2020. The perioperative period was defined as the 30 days before and after surgery. T2DM diagnoses occurring during survivorship were recorded. T2DM diagnoses were defined by a HgbA1c ≥6.5% or a random blood glucose ≥200 mg/dL. Sequelae of peri-operative T2DM and predictors of future T2DM were examined utilizing univariate analysis. RESULTS: Of 519 patients meeting inclusion criteria, 37 (7.1%) were diagnosed with T2DM in the perioperative period. Patients diagnosed with T2DM in the perioperative period had significantly higher BMI (p = 0.006) compared to no T2DM, but there were no significant differences in age (p = 0.20), ethnicity/race (p > 0.05) or ECOG score (p = 0.19). The rates of intraoperative complications between groups did not significantly differ, except for vascular complications (p = 0.005), and the incidence of any postoperative complication was higher in the perioperative T2DM group (p = 0.01). With a median follow-up of 29 months [range 11.6-49.0 months], an additional 18.3% (n = 88) of the cohort met diagnostic criteria for T2DM. BMI (p < 0.001), perioperative glucose (p < 0.001), and HgbA1c (p = 0.002) demonstrate risk for a T2DM diagnosis during survivorship. CONCLUSION(S): In this retrospective cohort of EC patients, 25.4% were diagnosed with T2DM, with the majority diagnosed in the survivorship period. Surgical management and subsequent surveillance of EC presents an opportunity to diagnose at-risk patients with T2DM.
引用
- Morton M, McLaughlin EM, Calo CA, et al. Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention? Gynecol Oncol. 2023. PMID: 37639902. doi:10.1016/j.ygyno.2023.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。